Yi-Long Wu, MD
Guangdong Provincial People's Hospital · Guangdong General Hospital (GGH)& Guangdong Academy of Medical Sciences · Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Yi-Long Wu, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:42 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07750704 · Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLCGuangdong Association of Clinical Trials · not yet recruiting · ALK Positive Non-small Cell Lung Cancer · principal investigator
- Ph2NCT06574347 · Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.Avistone Biotechnology Co., Ltd. · recruiting · Non-Small-Cell Lung Cancer
- Ph2NCT06092086 · Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLCGuangdong Association of Clinical Trials · recruiting · ALK Positive Non-small Cell Lung Cancer · principal investigator
- N/ANCT04007835 · Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKIGuangdong Association of Clinical Trials · unknown · NSCLC · study chair
- N/ANCT02113852 · Study of Blood, Tumor and Adjacent Normal Tissue Samples From Chinese Smoking Induced Lung Cancer PatientsGuangdong Association of Clinical Trials · completed · Non Small Cell Lung Cancer · principal investigator
- N/ANCT02042105 · A Prospective Epidemiologic Study of ALK-Positive NSCLC in ChinaGuangdong Association of Clinical Trials · completed · Non-small-cell Lung Cancer · principal investigator
- N/ANCT01740804 · Dynamic Circulating Tumor Cell (CTC) Changes During the Chemotherapy in NSCLCGuangdong Association of Clinical Trials · completed · Carcinoma, Non-Small-Cell Lung, Cell, Circulating Tumor · principal investigator
- Ph2/Ph3NCT01407822 · Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung CancerGuangdong Association of Clinical Trials · unknown · Non-small Cell Lung Cancer · principal investigator
- Ph3NCT01405079 · Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR MutationGuangdong Association of Clinical Trials · unknown · Non-small Cell Lung Cancer · principal investigator
- Ph2NCT00600587 · Induction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC)Guangdong Provincial People's Hospital · completed · Carcinoma, Non-Small-Cell Lung · principal investigator
- Ph3NCT00321334 · Survival Study of Docetaxel and Carboplatin as Neo-Adjuvant Vs Adjuvant Chemotherapy in Early Stage NSLCChinese Society of Lung Cancer · completed · Non-small Cell Lung Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:42 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in non-small cell lung cancer.